An interventional study of Aminoacid supplementation and Placebo in Obesity Morbid and Weight Loss, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.
Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 14th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 49th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–65
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–70
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–75 · Women only
Istituto Auxologico Italiano · Sites in Italy
Ages 18–80 · Men only
Istituto Auxologico Italiano · Sites in Italy
Ages 18–65
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 45 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 60 is close to the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 80 across the 25 interventional studies, 180 across the 29 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 5 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT06309563Istituto Auxologico ItalianoMetabolic Effects of a Diet Replaced With Essential Amino Acids | 2026-12-31 |
| NCT05917795Fondazione Policlinico Universitario Agostino Gemelli IRCCSEndoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Obesity, Morbid with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The effectiveness of low-protein diets supplemented with essential aminoacid (EAA) formulas in genetic disorders of amino acid (AA) catabolism, such as maple syrup urine disease (MSUD), is widely recognized (Blackburn PR et al. 2017). The main aim of the present study is to evaluate a difference in the effectiveness of a multidisciplinary rehabilitation program in patients with high degree of obesity with and without supplementation of this new formula of amino acids (essential + tricarboxylic acids - EAA-AC). For this reason, patients of both sexes, aged between 45 and 65, suffering from high-grade obesity will be recruited in Piancavallo. The enrolled patients divided, randomly, into two groups will be given: EAA-AC group a low-calorie and low-protein diet integrated with 4 sachets of EAA-AC supplement per day; the control group will follow a low-calorie and low-protein diet only with placebo. The parameters considered, after two weeks of treatment, will be: weight loss; the maintenance/recovery of muscle mass assessed through changes in body composition and functional tests (Hand grip, 6MWT or TUG) but also through the analysis of mitochondrial function in PBMC and circulating levels of mtDNA; the improvement of the glucose picture and the lipid profile.
1 month after discharge, patients will carry out an outpatient check-up to evaluate the maintenance of muscle mass using impedance testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Obesity ( >35kg/m2)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with obesity treated with essential aminoacids (EAA-AC)
Dietary Supplement: Aminoacid supplementation
Patients with obesity treated with placebo
Dietary Supplement: Placebo
Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
Also known as: EAA-AC, Controls
Low-calorie and low-protein diet + placebo for 2 weeks
Muscle mass
Change in muscle mass during weight loss assessed through changes in body composition
Time frame: At baseline and at 2 weeks after start of intervention
6 minute walking test (6MWT)
Change in distance covered in 6 minutes of walking during weight loss
Time frame: At baseline and at 2 weeks after start of intervention
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 40 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →